申请人:Takeda Chemical Industries, Ltd.
公开号:US05032594A1
公开(公告)日:1991-07-16
Novel tricyclic fused pyrimidine derivatives of the formula (I): ##STR1## wherein either one of R.sup.1 and R.sup.2 is hydrogen or an optionally substituted aralkyl group and the other is hydrogen, an optionally substituted aralkyl group or an aliphatic hydrocarbon group; R.sup.3 is hydrogen, an aliphatic hydrocarbon group or acyl group; and A is an optionally substituted divalent hydrocarbon chain having 2 to 4 carbon atoms and salts thereof are strong adenosine antagonists and activate cerebral functions and metabolisms, thus being useful as therapeutic or prophylactic agents for neurological or psychic changes caused by cerebral apoplexy, brain injury or cerebral atrophy.
式(I)的新型三环融合嘧啶衍生物:##STR1## 其中,R.sup.1和R.sup.2中的一个为氢原子或可选取代的芳基甲基基团,另一个为氢原子、可选取代的芳基甲基基团或脂肪烃基团;R.sup.3为氢原子、脂肪烃基团或酰基团;A为可选取代的二价碳氢链,其具有2至4个碳原子,其盐为强烈的腺苷酸拮抗剂,并激活脑功能和代谢,因此可用作治疗或预防因脑卒中、脑损伤或脑萎缩引起的神经或心理变化的治疗药物或预防药物。